News

GLP-1 weight-loss pills are coming. So are doubts about their potency.
Eli Lilly will seek regulatory approval for its next-generation weight-loss pill by year-end, based on data that suggests it ...
Fierce Biotech12h
Lilly's oral GLP-1 data 'as good as it gets' at 12% weight loss, exec says
As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to ...
MediaPost8m
GLP-1 Update: Novo Nordisk Sues Compounders, Lilly's Zepbound Soars
Novo Nordisk filed 14 new lawsuits against compounders claiming to contain semaglutide, the component of its Ozempic and ...
Eli Lilly beats earnings for second quarter on strong GLP-1 sales, stock dives on GLP-1 pill trial results
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
Where Eli Lilly stands after Q2 beat but weak GLP-1 pill data
Eli Lilly (LLY) raised its full-year forecast after beating second quarter expectations, but shares slipped as its ...
Devdiscourse9h
Eli Lilly's GLP-1 Pill: A Diminished Competitor in the Obesity Drug Race
Eli Lilly's experimental GLP-1 pill showed a 12.4% body weight reduction, less than Novo Nordisk's injectable Wegovy in a ...
Eli Lilly raises 2025 revenue guidance to $60B-$62B while expanding GLP-1 pipeline and production
Q2 2025 Management View CEO David A. Ricks highlighted a strong quarter, stating, "Q2 was a strong quarter. We delivered robust revenue growth, shared top line clinical data from multiple Phase III ...
Daily oral GLP-1 pill could be just as effective as weekly shots: Drugmaker
Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 shots.